Crétien Aurore, Hurtaud Corinne, Moniz Hélène, Proust Alexis, Marie Isabelle, Wagner-Ballon Orianne, Choesmel Valérie, Gleizes Pierre-Emmanuel, Leblanc Thierry, Delaunay Jean, Tchernia Gil, Mohandas Narla, Da Costa Lydie
Service, d'Hématologie biologique, Hôpital, Robert Debré, 48 boulevard Sérurier, 75019 Paris, France.
Haematologica. 2008 Nov;93(11):1627-34. doi: 10.3324/haematol.13023. Epub 2008 Sep 2.
Mutations in the ribosomal protein S19 gene (RPS19) have been found in 25% of patients with Diamond-Blackfan anemia, a rare syndrome of congenital bone marrow failure characterized by erythroblastopenia and various malformations. Mechanistic understanding of the role of RPS19 in normal erythropoiesis and in the Diamond-Blackfan anemia defect is still poor. However, defective ribosome biogenesis and, in particular, impaired 18S ribosomal RNA maturation have been documented in association with various identified RPS19 mutations. Recently, new genes, all encoding ribosomal proteins, have been found to be mutated in Diamond-Blackfan anemia, adding further support to the concept that ribosome biogenesis plays an important role in regulating erythropoiesis. We previously showed variability in the levels of expression and subcellular localization of a subset of RPS19 mutant proteins.
To define the mechanistic basis for this variability better, we studied a large number of mutant proteins and characterized both RPS19 expression level using a specific antibody against RPS19 and RPS19 subcellular localization after transfection of Cos-7 cells with various green fluorescent protein-RPS19 mutants. To investigate the role of the proteasome in RPS19 degradation, we examined the effect of various proteasome inhibitors, namely lactacystin, MG132, and bortezomib on RPS19 expression and subcellular localization
We found two distinct classes of RPS19 protein defects in Diamond-Blackfan anemia based on the stability of the mutant proteins: (i) slightly decreased to normal levels of expression and normal nucleolar localization and (ii) markedly deficient expression and failure to localize to the nucleolus. All the proteasome inhibitors tested were able to restore the expression levels and normal subcellular localization of several unstable mutant proteins.
Our findings demonstrate an important role for the proteasomal degradation pathway in regulating the expression levels and nucleolar localization of certain mutant RPS19 proteins in Diamond-Blackfan anemia.
在25%的先天性纯红细胞再生障碍性贫血患者中发现了核糖体蛋白S19基因(RPS19)突变,先天性纯红细胞再生障碍性贫血是一种罕见的先天性骨髓衰竭综合征,其特征为成红细胞减少和各种畸形。对RPS19在正常红细胞生成及先天性纯红细胞再生障碍性贫血缺陷中所起作用的机制理解仍很匮乏。然而,已证明核糖体生物合成缺陷,尤其是18S核糖体RNA成熟受损与各种已鉴定的RPS19突变有关。最近,发现一些新基因(均编码核糖体蛋白)在先天性纯红细胞再生障碍性贫血中发生突变,这进一步支持了核糖体生物合成在调节红细胞生成中起重要作用这一概念。我们之前发现RPS19突变蛋白亚群的表达水平和亚细胞定位存在差异。
为了更好地确定这种差异的机制基础,我们研究了大量突变蛋白,并使用抗RPS19的特异性抗体对RPS19表达水平进行了表征,以及在用各种绿色荧光蛋白-RPS19突变体转染Cos-7细胞后对RPS19亚细胞定位进行了表征。为了研究蛋白酶体在RPS19降解中的作用,我们检测了各种蛋白酶体抑制剂,即乳胞素、MG132和硼替佐米对RPS19表达和亚细胞定位的影响。
基于突变蛋白的稳定性,我们在先天性纯红细胞再生障碍性贫血中发现了两类不同的RPS19蛋白缺陷:(i)表达水平略有下降至正常水平且核仁定位正常,以及(ii)表达明显不足且无法定位于核仁。所有测试的蛋白酶体抑制剂都能够恢复几种不稳定突变蛋白的表达水平和正常亚细胞定位。
我们的研究结果表明蛋白酶体降解途径在调节先天性纯红细胞再生障碍性贫血中某些突变RPS19蛋白的表达水平和核仁定位方面起着重要作用。